Last reviewed · How we verify
NCT05901233
Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia
NA trial testing Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS) in Primary Progressive Aphasia in 10 participants. Enrolling by invitation.
30 August 2026
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 10 July 2023 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)
- Remotely supervised sham tDCS (RS-sham-tDCS)
- Lexical Retrieval Training (LRT)
- Video Implemented Script Training in Aphasia (VISTA)
Conditions studied
- Primary Progressive Aphasia — all drugs for Primary Progressive Aphasia →
Sponsor
University of Texas at Austin
Who can join
Eligibility, any sex, with Primary Progressive Aphasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary progressive aphasia (PPA) is a disorder characterized by gradual decline in speech-language ability caused by underlying neurodegenerative disease. PPA is a devastating condition that can affect adults as young as their 50's, depriving them of the ability to communicate and function in society. Along with Alzheimer's Disease and other Alzheimer's Disease Related Dementias (AD/ADRD), PPA is now identified earlier and with greater precision. Increasingly, patients and families seek options for behavioral and neuromodulatory treatments to address PPA's devastating effects on communication, prolong speech-language skills, and maximize quality of life. Studies have documented the robust benefits of speech-language telerehabilitation methods for persons with PPA, with in-home treatment resulting in immediate and long-term benefits. This investigation aims to further enhance the potency of these treatment approaches by pairing them with tailored neuromodulatory intervention that targets critical brain networks supporting treatment in each clinical subtype of PPA. The study will evaluate the feasibility and preliminary benefit of home-based transcranial direct current stimulation (tDCS) combined with evidence-based speech-language telerehabilitation methods. tDCS will be delivered to patients in their own homes and site of stimulation will be tailored for each clinical subtype of PPA. This project has the potential to enhance clinical management and rehabilitation for individuals with PPA by establishing the benefit of behavioral and neuromodulatory treatment that is neurobiologically-motivated and accessible for patients and families.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05901233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Progressive Aphasia
Currently open trials in the same condition.
- NCT06191198 — Communication Bridge 3 Study · Phase 2 · recruiting
- NCT06211374 — Communication Bridge Pilot Study · NA · active not recruiting
- NCT05386394 — Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia · Phase 2 · recruiting
- NCT05741853 — Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia · NA · recruiting
- NCT05443633 — Enhancing Language Function in Aphasia · NA · recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05901233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 8 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05901233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing